References
- Calne RY , SellsRA, PenaJRet al. Induction of immunological tolerance by porcine liver allografts. Nature223(5205), 472–476 (1969).
- Boon T , CerottiniJC, Van Den EyndeB, Van Der BruggenP, Van PelA. Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol.12, 337–365 (1994).
- Vanky F , KleinE. Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int. J. Cancer29(5), 547–553 (1982).
- Hato T , GoyalL, GretenTF, DudaDG, ZhuAX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology60(5), 1776–1782 (2014).
- Flecken T , SchmidtN, HildSet al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology59(4), 1415–1426 (2014).
- Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
- Crispe IN . Immune tolerance in liver disease. Hepatology doi:10.1002/hep.27254 (2014) ( Epub ahead of print).
- Kingham TP , ChaudhryUI, PlitasG, KatzSC, RaabJ, DematteoRP. Murine liver plasmacytoid dendritic cells become potent immunostimulatory cells after Flt-3 ligand expansion. Hepatology45(2), 445–454 (2007).
- Sun X , GongZJ, WangZWet al. IDO-competent-DCs induced by IFN-gamma attenuate acute rejection in rat liver transplantation. J. Clin. Immunol.32(4), 837–847 (2012).
- Jurgens B , HainzU, FuchsD, FelzmannT, HeitgerA. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood114(15), 3235–3243 (2009).
- Heo J , ReidT, RuoLet al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med.19(3), 329–336 (2013).
- Sangro B , Gomez-MartinC, De La MataMet al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol.59(1), 81–88 (2013).
- Topalian SL , WeinerGJ, PardollDM. Cancer immunotherapy comes of age. J. Clin. Oncol.29(36), 4828–4836 (2011).
- Gajewski TF , WooSR, ZhaYet al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol.25(2), 268–276 (2013).
- Greten TF , DuffyAG, KorangyF. Hepatocellular carcinoma from an immunologic perspective. Clin. Cancer Res.19(24), 6678–6685 (2013).
- Okuma K , YamashitaH, NiibeY, HayakawaK, NakagawaK. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report. J. Med. Case Rep.5, 111 (2011).
- Nakanishi M , ChumaM, HigeS, AsakaM. Abscopal effect on hepatocellular carcinoma. Am. J. Gastroenterol.103(5), 1320–1321 (2008).
- Ohba K , OmagariK, NakamuraTet al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut43(4), 575–577 (1998).
- Greten TF , KorangyF. Radiofrequency ablation for the treatment of HCC‐‐maybe much more than simple tumor destruction?J. Hepatol.53(4), 775–776 (2010).
- Epstein RJ , LeungTW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin. Cancer. Res.13(1), 11–17 (2007).